Uveoretinal Adverse Effects Presented during Systemic Anticancer Chemotherapy: a 10-Year Single Center Experience

• Published in: Journal of Korean medical science Vol. 33; no. 7; pp. e55 - 44
• Main Authors: Cho, Ah Ran, Yoon, Young Hee, Kim, June-Gone, Kim, Yoon Jeon, Lee, Joo Yong
• Format: Journal Article
• Language: English
• Published: Korea (South) The Korean Academy of Medical Sciences 12.02.2018; 대한의학회
• Subjects: Adult; Aged; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Corneal Diseases - diagnosis; Corneal Diseases - etiology; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Neoplasms - drug therapy; Neoplasms - pathology; Original; Retrospective Studies; Uveitis - diagnosis; Uveitis - etiology; Visual Acuity; Young Adult; 의학일반; Chemotherapy; Targeted Molecular Therapy; Drug Toxicity; Uveitis; Cancer Chemotherapy Agents
• ISSN: 1011-8934; 1598-6357; 1598-6357
• DOI: 10.3346/jkms.2018.33.e55

The present study describes our 10-year experience with uveoretinal adverse events that manifest because of chemotherapy. A retrospective chart review was performed for all patients who presented to the ophthalmologic department while undergoing systemic chemotherapy between July 2005 and June 2015. A total of 55 patients (mean age, 51.2 years, 38 women [69.1%]) suspected of having uveoretinal disease owing to the use of chemotherapeutic agents alone were enrolled. Breast cancer was the predominant disease (36.4%); noninfectious anterior uveitis (21.8%) was the most common condition. Bilateral involvement was observed in 16 patients (29.1%). Although cisplatin (21.8%) was the most commonly used drug, daunorubicin, cytarabine, tamoxifen, toremifene, and imatinib were also frequently used. The median duration until ophthalmologic diagnosis was 208.5 days (range, 19-5,945 days). The proportion of patients with final visual acuity (VA) < 20/40 Snellen VA (0.5 decimal VA) was 32.7%. However, no relationship was observed between final VA < 20/40 and age, sex, therapeutic agents, and metastasis. Uveoretinal complications were mostly mild to moderate and exhibited a favorable response to conservative therapy. A considerable number of patients exhibited significant irreversible loss of vision after cessation of the causative chemotherapeutic agent. Ophthalmological monitoring is required during chemotherapy.